Atara is among a new breed of “virtual” biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations. They are becoming increasingly common as investors seek to mitigate the huge risks of bringing drugs to market, a process that can cost as much as $1.8 billion, according to industry estimates.
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
